13FINSTITUTION · CIK 0001263508 · 2026-Q2 · Filed Aug 14, 2026
Baker Bros. Advisors
BAKER BROS. ADVISORS LP
$20.0B
13F long value · 2026-Q2 Positions84
CategoryAsset manager
Quarters tracked9
●#317 of 556 by 13F long value
Size rank 5/10
7NEW2ADD32×+3TRIM8EXIT
Snapshot
Baker Bros. Advisors's 13F portfolio at a glance: size, concentration and this quarter's activity.
13F long value
$20.0B
Positions
84 (1 unmapped)
Top 84 long weight
99.9%
Quarters tracked
9
Latest 13F filed
Aug 14, 2026
New positions
7
Exits / near-exits
8
13F long value by quarter
Reported long equity value each quarter: fund flows plus market moves. Option notional is not included.
Top holdings · 2026-Q2
The fund's largest reported positions. The long positions shown cover 99.9% of the long value.
| Ticker | Issuer | Weight | Value | Shares | Since 2026-Q2 |
|---|---|---|---|---|---|
| INCY INCYTE CORP | INCYTE CORP | 17.5% | $3.5B | 30.8M | +6.1% |
| ONC BeOne Medicines Ltd. | BeOne Medicines Ltd. | 12.6% | $2.5B | 8.8M | +44.3% |
| RVMD Revolution Medicines, Inc. | Revolution Medicines, Inc. | 10.7% | $2.1B | 11.4M | -10.9% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | MADRIGAL PHARMACEUTICALS, INC. | 5.8% | $1.2B | 2.1M | -21.0% |
| ACAD ACADIA PHARMACEUTICALS INC | ACADIA PHARMACEUTICALS INC | 5.4% | $1.1B | 42.9M | -26.2% |
| KYMR Kymera Therapeutics, Inc. | Kymera Therapeutics, Inc. | 5.0% | $992.7M | 8.7M | +9.7% |
| INSM INSMED Inc | INSMED Inc | 4.7% | $937.8M | 8.8M | +15.3% |
| CELC Celcuity Inc. | Celcuity Inc. | 4.2% | $828.2M | 7.9M | -42.1% |
| KOD Kodiak Sciences Inc. | Kodiak Sciences Inc. | 3.9% | $776.1M | 19.9M | +158.5% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | RHYTHM PHARMACEUTICALS, INC. | 3.1% | $622.3M | 5.6M | -3.2% |
| PRAX Praxis Precision Medicines, Inc. | Praxis Precision Medicines, Inc. | 2.9% | $587.0M | 1.8M | -7.3% |
| ALKS Alkermes plc. | Alkermes plc. | 2.6% | $524.6M | 10.0M | -11.2% |
| SMMT Summit Therapeutics Inc. | Summit Therapeutics Inc. | 2.4% | $477.7M | 32.8M | -18.9% |
| GRAL GRAIL, Inc. | GRAIL, Inc. | 1.4% | $275.0M | 4.0M | +54.7% |
| ABCL AbCellera Biologics Inc. | AbCellera Biologics Inc. | 1.3% | $259.1M | 33.0M | +41.7% |
Quarterly changes · 2026-Q2
What Baker Bros. Advisors opened, added, trimmed and exited this quarter, largest dollar moves first.
| Action | Ticker | Issuer | Prev shares | Curr shares | Change | Value Δ |
|---|---|---|---|---|---|---|
| EXIT | ABVX EXIT Abivax S.A. | Abivax S.A. | 875.8K | 0 | -100.0% | -$97.5M |
| TRIM | EWTX TRIM Edgewise Therapeutics, Inc. | Edgewise Therapeutics, Inc. | 6.6M | 3.7M | -43.7% | -$56.7M |
| ADD | IDYA ADD IDEAYA Biosciences, Inc. | IDEAYA Biosciences, Inc. | 3.9M | 5.0M | +26.9% | +$55.2M |
| EXIT | SYRE EXIT Spyre Therapeutics, Inc. | Spyre Therapeutics, Inc. | 1.0M | 0 | -100.0% | -$50.4M |
| 2×+ | RLAY 2×+ Relay Therapeutics, Inc. | Relay Therapeutics, Inc. | 1.2M | 2.8M | +143.7% | +$41.3M |
| NEW | FTH NEW Faeth Therapeutics, Inc. | Faeth Therapeutics, Inc. | 0 | 1.3M | New | +$32.2M |
| EXIT | CNTA EXIT Centessa Pharmaceuticals plc | Centessa Pharmaceuticals plc | 670.8K | 0 | -100.0% | -$26.6M |
| ADD | CLDX ADD Celldex Therapeutics, Inc. | Celldex Therapeutics, Inc. | 665.4K | 1.2M | +77.7% | +$22.9M |
| EXIT | IMCR EXIT Immunocore Holdings plc | Immunocore Holdings plc | 734.4K | 0 | -100.0% | -$22.1M |
| EXIT | CTNM EXIT Contineum Therapeutics, Inc. | Contineum Therapeutics, Inc. | 1.4M | 0 | -100.0% | -$18.6M |
Conviction over time
Portfolio weight of the current top long holdings, quarter by quarter; rising weight = growing conviction.